Detalles de la búsqueda
1.
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Blood
; 133(9): 893-901, 2019 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559259
2.
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Eur J Haematol
; 104(3): 251-258, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838747
3.
Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.
Eur J Nucl Med Mol Imaging
; 45(6): 931-940, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29480328
4.
Dominant inherited ß-thalassemia intermedia in a Polish family due to a novel frameshift mutation in HBB.
Pediatr Blood Cancer
; 70(10): e30511, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37353956
5.
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Blood
; 117(12): 3409-20, 2011 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21220747
6.
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Blood
; 114(26): 5342-51, 2009 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-19850739
7.
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Am J Hematol
; 86(7): 533-9, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21538470
8.
Attenuation of canonical NF-κB signaling maintains function and stability of human Treg.
FEBS J
; 288(2): 640-662, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386462
9.
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Neoplasia
; 23(12): 1183-1191, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731787
10.
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Am J Pathol
; 175(6): 2416-29, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19893034
11.
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Blood Adv
; 4(6): 997-1005, 2020 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32176765
12.
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Exp Hematol
; 36(10): 1244-53, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18619723
13.
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
J Clin Oncol
; 37(23): 1997-2007, 2019 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31112476
14.
Plasma levels of P-selectin are determined by platelet turn-over and the P-selectin Thr715Pro polymorphism.
Thromb Res
; 121(4): 573-9, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-17698171
15.
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Exp Hematol
; 35(10): 1510-21, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17681669
16.
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease.
Blood Adv
; 7(10): 1987-1990, 2023 05 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36322823
17.
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Haematologica
; 92(11): 1451-9, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18024392
18.
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.
Leuk Lymphoma
; 48(10): 1997-2007, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917967
19.
Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma.
Wien Klin Wochenschr
; 119(7-8): 228-34, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17492350
20.
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Cancer Res
; 65(20): 9436-44, 2005 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16230407